

June 1, 2009

GENESISCS PERFORMANCE UPDATE MEMO

To our valued customers, in an effort to continue our relentless pursuit for optimal clinical outcomes, EmCyte Corporation will now be providing the **Pilot Automated Aspirating System** for use with the GenesisCS and GenesisCS MINI Component Concentrating Systems. The Pilot Automated Aspirating System is designed to work with a specially developed **Sequester Line** that will soon be coming in every GenesisCS and GenesisCS MINI kit. This line is equipped with a sensor connector that will detect the buffy-coat layer of the bone marrow aspirate and platelet concentrate, allowing the end user to easily and consistently aspirate a pure and perfect product with consistently high yields in the final product sample. This new system enhancement has allowed EmCyte Corporation to further establish our performance moto of "Gentle Centrifugation" by further reducing the centrifuge speeds of the Performance Centrifuge Machine to **2000RPMs** with a slight increase in time to **15 minutes**, while maintaining the **Zero Brake** deceleration. Elaborate testing has shown that this change allows more platelets to migrate into the buffycoat layer during centrifugation. From this day forward the performance machines will be shipped with this new protocol setting.

The Sequester Lines will be found in every GenesisCS and GenesisCS MINI Kit in the fall of 2009. In the meantime, you can take advantage of the enhanced Gentle Centrifugation settings of your performance machine today. We are encouraging all of our customers to adapt this machine protocol for improved yields. Change your machine settings to **2000RPM, 15 minutes** and **0 Brake**.

For more information on the Pilot Automated Aspirating System with the Sequester line, you may visit <http://www.emcyte.com>, click on the "**PRODUCT INFO**" tab and then select "**VIDEO DEMOS**". You may also evaluate or demo a product by clicking on the "**RESOURCES**" tab and then select "**Demo a Product**".

We want to thank you for your business.

Respectfully,



Patrick Pennie
President
EmCyte Corporation